The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Unattributed VC - IV | Alive

Total Raised


Last Raised

$22M | 14 yrs ago

About Acorn Cardiovascular

Acorn Cardiovascular is a medical device company pursuing treatments for patients with heart failure. Acorn

Acorn Cardiovascular Headquarter Location

601 Campus Drive Suite One

Saint Paul, Minnesota, 55112,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Acorn Cardiovascular Patents

Acorn Cardiovascular has filed 8 patents.

patents chart

Application Date

Grant Date


Related Topics




Radio telescopes, Medical equipment, Drug delivery devices, Neurological disorders, Interferometric telescopes


Application Date


Grant Date



Related Topics

Radio telescopes, Medical equipment, Drug delivery devices, Neurological disorders, Interferometric telescopes



Latest Acorn Cardiovascular News

Preceptis seeks $2.5 million to develop pediatric medical device

Jan 5, 2012

Share / Jan 5, 2012 at 9:55 AM A Minnesota pediatric medical device company is seeking $2.5 million, according to documents filed with the Securities & Exchange Commission. Preceptis Medical, which is developing a solution that will allow ear, nose and throat specialists to perform ear tube surgeries safely on children right in their offices, has already raised $500,000 by issuing debt and convertible debt. The company’s CEO – Steve Anderson – declined comment. But in an interview last May , Anderson said that at minimum he was looking to raise $5 million and if market appetite was greater he would raise up to $10 million. Advertisement The target market, he said, would consist of the 1.3 million to 1.5 million ear tube surgeries that are performed in the operating room annually on children. “What we are doing is that we are trying to come up with solutions for moving those procedures out of the OR so that the kids do not have to undergo general anesthesia,” Anderson said at the time. “We have come up with a way of safely delivering ear tubes right in the ENT’s office.” At the time, Anderson also said that the device that Preceptis was developing would bring cost savings because it would transfer surgeries out of hospitals into doctor’s offices. By transferring those surgeries out of hospitals and ambulatory surgical centers to the ENT’s office, health insurers can save 70 percent per procedure, Anderson said. Anderson was president of Acorn Cardiovascular , which capitulated after a long battle with the Food and Drug Administration, which repeatedly denied approving the company’s heart device. After raising $100 million in venture capital, Anderson was forced to close Acorn. In late 2010, he sold its intellectual property to an undisclosed company and liquidated its assets before moving on to create Preceptis, which is developing a lower risk device than Acorn.  

  • When was Acorn Cardiovascular founded?

    Acorn Cardiovascular was founded in 1996.

  • Where is Acorn Cardiovascular's headquarters?

    Acorn Cardiovascular's headquarters is located at 601 Campus Drive, Saint Paul.

  • What is Acorn Cardiovascular's latest funding round?

    Acorn Cardiovascular's latest funding round is Unattributed VC - IV.

  • How much did Acorn Cardiovascular raise?

    Acorn Cardiovascular raised a total of $92.95M.

  • Who are the investors of Acorn Cardiovascular?

    Investors of Acorn Cardiovascular include New Enterprise Associates, SightLine Partners, Credit Suisse First Boston, Thoratec, Fidelity Investments and 13 more.

  • Who are Acorn Cardiovascular's competitors?

    Competitors of Acorn Cardiovascular include SynCardia Systems, Corassist Cardiovascular, Sonivate Medical, Penumbra, Carticept Medical and 10 more.

You May Also Like

Sonivate Medical

Sonivate Medical develops and manufactures technologies to reduce healthcare cost and expand access to diagnostic imaging. The SonicEye is a fingertip-mounted ultrasound probe that enables imaging while leaving both hands free to do work with simultaneous tactile feedback.

Corassist Cardiovascular

CorAssist is a clinical stage medical device company developing innovative therapeutic products for treating heart failure with preserve ejection fraction. The company's proprietary technology enables the first implantation of devices that directly improves cardiac diastolic function.


Antivirals is engaged in the discovery of agents that inhibit replication of human pathogenic viruses.


Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.


CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

Cleveland Heart

Cleveland Heart has partnered with the Cleveland Clinic to develop the next generation of mechanical cardiac circulatory assist devices with the potential to provide a complete range of treatment options for patients suffering from irreversible end-stage heart failure.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.